HIV infection, Treatment-experienced patients
Monitor viral load prior to initiation or modification of treatment.
Monitor CD4 cell counts prior to initiation or with modification of ARV treatment and every 3-6 months; thereafter during at least the first 2 years of treatment.
Monitor hepatitis B screening.
Perform hepatitis C antibody testing prior to initiation or modification of ARV treatment.
Monitor ALT,AST, and total bilirubin, basic chemistry including serum sodium, potassium, bicarbonate, chloride, BUN, creatinine, and creatinine-based estimated glomerular filtration rate.
Common
Serious
Multiple drug-drug interactions
Contraindications:
Antimicrobial class: Antiretroviral, Non-nucleoside reverse transcriptase inhibitor
Pregnancy category: B
Average serum half life: 9.05 - 41 hours
Urine penetration: Therapeutic
CSF penetration: Therapeutic
Precautions: Immune reconstitution syndrome has been reported with combination ARV therapy; patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections.
Discontinue immediately and monitoring recommended if hypersensitivity reactions or severe rash occurs.
항생제
